RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study

Abstract Previous studies have shown the clinical benefit of rechallenging the RAF pathway in melanoma patients previously treated with BRAF inhibitors. 44 patients with multiple tumors harboring RAF alterations were rechallenged with a second RAF inhibitor, either as monotherapy or in combination w...

Descripció completa

Dades bibliogràfiques

Autors principals:	Blessie Elizabeth Nelson, Jason Roszik, Jibran Ahmed, Carmelia Maria Noia Barretto, Mirella Nardo, Erick Campbell, Amber M Johnson, Sarina A. Piha-Paul, Isabella C. Glitza Oliva, Shiao-Pei Weathers, Maria Cabanillas, Milind Javle, Funda Meric-Bernstam, Vivek Subbiah
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2024-03-01
Col·lecció:	Molecular Cancer
Matèries:	Rechallenge RAF pathway BRAF inhibitors BRAF-altered solid tumors
Accés en línia:	https://doi.org/10.1186/s12943-024-01982-4
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!